Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alfred Liddle

Physician Assistant Lincoln, RI Physician Assistant

NPI 1205813615 CMS profile 10783934

2 Wake Robin Rd, Lincoln, RI 02865

Open in the dashboard

General payments

$23,162

701 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alfred Liddle of Lincoln, RI is reported in the CMS Open Payments database as having received $23,162 across 701 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,741 145
2024 General $4,596 147
2023 General $4,987 144
2022 General $4,925 166
2021 General $3,913 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alfred Liddle
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Alfred Liddle were reported at $4,741. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Alfred Liddle Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,913 $132 $37–$438 $132
2022 $4,925 $155 $48–$522 $149
2023 $4,987 $167 $52–$557 $160
2024 $4,596 $178 $55–$600 $164
2025 $4,741 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $3,302 87 payments
  2. Amgen Inc. $1,939 53 payments
  3. AbbVie, Inc. $1,739 50 payments
  4. GlaxoSmithKline, LLC. $1,635 42 payments
  5. Novo Nordisk Inc $1,417 60 payments
  6. Abbott Laboratories $1,298 20 payments
  7. Lilly USA, LLC $1,248 53 payments
  8. Janssen Pharmaceuticals, Inc $1,236 32 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $1,063 17 payments
  10. Vanda Pharmaceuticals Inc. $836 30 payments
  11. Other $7,450 257 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $23,162 701 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $1,426 45 payments
  2. Ozempic $1,232 55 payments
  3. XARELTO $1,223 31 payments
  4. FreeStyle Libre 3 $1,174 18 payments
  5. RYBELSUS $1,137 55 payments
  6. Otezla $983 29 payments
  7. Repatha $883 28 payments
  8. AIRSUPRA $880 23 payments
  9. BREZTRI $817 15 payments
  10. NURTEC ODT $814 14 payments
  11. Other $15,745 566 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 91 drugs

Part D claims

4,646

Median for Physician Assistant: 241

Drug cost

$360,034

Median for Physician Assistant: $4,110

Branded share of claims

21.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 73 $67,701
Eliquis Apixaban Brand 70 $53,588
Jardiance Empagliflozin Brand 34 $45,974
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 54 $37,927
Farxiga Dapagliflozin Propanediol Brand 45 $30,992
Trulicity Dulaglutide Brand 12 $15,194
Xarelto Rivaroxaban Brand 21 $14,622
Tresiba Flextouch U-100 Insulin Degludec Brand 13 $7,246
Linzess Linaclotide Brand 12 $6,180
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 11 $5,774

The 10 drugs with the highest cost, of 91 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$29,936

Medicare's payments for the services billed

Medicare patients

101

Average age 71

Services billed

525

39 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 38%
Ischemic heart disease 29%
Chronic kidney disease 26%
Atrial fibrillation 19%
COPD 18%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $213
  • Lilly USA, LLC $107
$320 34 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $319
$319 — —
VRAYLAR
  • AbbVie, Inc. $310
$310 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $298
$298 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $290
$290 45 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

701 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record